期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肠促胰岛素相关药物的临床作用研究进展 被引量：4

The research progress of the clinical function of the related agents of incretin
下载PDF
导出
摘要 肠促胰岛素是一类在食物刺激下由肠道细胞分泌并能促使胰岛素分泌的激素,与之相关并已用于临床的药物主要包括胰高血糖素样肽-1类似物和二肽基肽酶-4抑制剂两类。本文简要介绍肠促胰岛素相关药物的临床作用研究进展。 Incretin is a hormone released from the intestine cells under the stimulation of food and can promote the insulin secretion. The related agents used in the clinic mainly include two types, the glucagon-like peptide-1 （GLP-1） receptor agonists and dipeptidyl peptidase-4 （DPP-4） inhibitors. This review introduces the research progress of the clinical function of the related agents of incretin.
作者 黄新梅 刘军
机构地区 复旦大学附属上海市第五人民医院内分泌代谢科
出处 《上海医药》 CAS 2013年第7期7-10,14,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 肠促胰岛素 胰高血糖素样肽-1受体激动剂 二肽基肽酶-4抑制剂 incretin glucagon-like peptide-1 receptor agonists dipeptidyl peptidase-4 inhibitors
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献31

  • 1Elrick H, Stimmler L, Hlad C J, et al. Plasma insulin response to oral and intravenous glucose administration [J]. J Clin Endocrinol Metab,1964, 24(10): 1076-1082.
  • 2Hoist J J, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus [J]. Mol Cell Endocrinol, 2009, 297(1-2): 127-136.
  • 3Knop FK, Vilsboll T, Hojberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? [J]. Diabetes, 2007, 56(8): 1951-1959.
  • 4Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus [J]. J Clin Invest, 1993, 91(1): 301-307.
  • 5Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review [J]. Clin Ther, 2012, 34(6): 1247-1258.
  • 6Fehse F, Trautmann M, Holst J J, et al. Exenatide augments first and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J]. J Clin Endocrinol Metab, 2005, 90(11): 5991-5997.
  • 7Bunck MC, Diamant M, Comer A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial [J]. Diabetes Care, 2009, 32(5): 762-768.
  • 8纪立农.肠促胰素的胰腺外作用研究进展[J].中华内分泌代谢杂志,2011,27(6):543-546. 被引量：9
  • 9Alcantara AI, Morales M, Delgado E, et al. Exendin-4 agonist and exendin (9-39) amide antagonist of the GLP-1 (7-36) amide effects in liver and muscle [J]. Arch Biochem Biophys, 1997, 341(1): 1-7.
  • 10Marquez L, Trapote MA, Luque MA, et al. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1 (7-36) amide on rat liver and adipose tissue [J]. Cell Biochem Funct, 1998, 16(1): 51-56.

二级参考文献45

  • 1Drucker D J, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase4 inhibitors in type 2 diabetes. Lancet, 2006,368, 1696-1705.
  • 2Salehi M, Aulinger BA, D'Alessio DA. Targeting β-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev, 2008,29:367-379.
  • 3Holz GG 4th, Kiihtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-I (7-37). Nature, 1993,361:362-365.
  • 4Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology, 2007,132 : 2131-2157.
  • 5Kim S J, Winter K, Nian C. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase ( PI3-K )/ protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxol and downregulation of bax expression. J Biol Chem, 2005,280:22297-22307.
  • 6Toil-Nielsen MB, Damholt MB, Madsbad S. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 2001,86:3717-3723.
  • 7Ding WG, Gromada J. Protein kinase A-dependent stimulation of exocytosis in mouse pancreatic beta-cells by glucose-dependent insulinotropic polypeptide. Diabetes, 1997,46:615-621.
  • 8Knop FK. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes, 2007,56 : 1951-1959.
  • 9Nauck MA, Heimesaat MM, Hoist JJ. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide I but not of synthetic hunmn gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest, 1993,91:301-307.
  • 10Goke R, Larsen P J, Mikkelsen JD. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-I binding sites. Eur J Neurosci, 1995,7:2294-2300.

共引文献8

同被引文献45

  • 1Russell-Jone D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue[ J 1. Mol Cell Endo- crinol,2009 (297) :137-140.
  • 2Knudsen LB, Knudsen SM, Wilken M, et al. Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its ef- ficacy[J]. Diabetes,2003(52) :A321-322.
  • 3Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitue [J]. Endocr Praet,2007 ( 13 ) : 1-68.
  • 4Liu H, Dear AE, Knucsen LB, et al. A long-acting glucagon-like pep- tide-1 analogue attenuates induction of plasminogen activator inhibi- tor type-1 and vascular adhesion molecules [ J ]. J Endocrinol, 2009 (201) :59-66.
  • 5Bunck MC,Comer A,Eliasson B, et al. One-year treatment with ex- enatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress [ J ]. Atherosclerosis, 2010,212 ( 1 ) : 223 -229.
  • 6Okerson T, Yan P, Stonehouse A, et al. Effects of exenatide on sys- tolic blood pressure in subjects with type 2 diabetes [ J ]. Am J Hy- pertens,2010(23) :334-339.
  • 7Nauck M,Frid A,Hermansen K,et al. Efficacy and safety compari- son of liraglutide, glimepiride, and placebo, all in combination with metformin,in type 2 diabetes : the LEAD ( liraglutide effect and ac- tion in diabetes ) -2 study [J]. Diabetes Care, 2009 ( 3 ) :84- 90.
  • 8Zinman B, Gerieh J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with met- formin and thiazolidinedione in patients with type 2 diabetes ( LEAD-4 Met+TZD) [J]. Diabetes Care ,2009 ( 32 ) :1224-1230.
  • 9Fonseca V. In subjects with type 2 diabetes, liraglutide, a once-dai- ly human GLP-1 analog, reduce systolic blood pressure with negli- gible impact from weight loss [ J ]. Diabetologia,2010 ( 53 ) : S1292.
  • 10Katout M, Zhu H, Rutsky J, et al. Effect of GLP-I mimetics on blood pressure and relationship to weight loss and glycemia lowering: re- suits of a systematic meta-analysis and meta-regression [ J ]. Am J Hypertens,2014,27( 1 ) :130-139.

引证文献4

二级引证文献14

上海医药
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部